It seems that interest is growing for starting Phase 1 trials in Australia due in part to the comparative ease of regulatory submission, the scientific confidence in the results and the lower costs. There is quite a bit of regulatory history in Australia that might contribute to a combination of adherence to good clinical practices and favorable regulatory procedures. More...
PDI Blog
1